Although polyneuropathies associated with IgM and IgG monoclonal gammopathies have been well described, polyneuropathy with IgA monoclonal gammopathy of undetermined significance (MGUS) is less commonly seen and has not been well studied. We reviewed the clinical and electrodiagnostic features of 5 such patients, and the sural nerve biopsy findings in 4 of them. One patient was diabetic, while 4 were free of other diagnoses commonly associated with neuropathy. Clinical presentations were varied. Electrodiagnostic and histological studies ranged from primary demyelination to primary axon loss to a mixed axonaVdemyelinating picture. Three patients who were treated appeared to respond to prednisone or intravenous gamma globulin, despite clear clinical, electrodiagnostic, and histological differences. We conclude that the polyneuropathy associated with IgA MGUS is heterogeneous, similar to that in IgM and IgG MGUS. A trial of immunomodulating therapy appears to be warranted in such patients if the neuropathy is sufficiently severe. 0 1993 John Wiley & Sons, Inc.
exhibit primarily axonal features, while others primarily show demyelination. In contrast, descriptions of patients with polyneuropathy and IgA monoclonal gammopathy-particularly IgA monoclonal gammopathy of undetermined significance (MGUS)-are rare. In an attempt to describe such patients more completely, we have reviewed clinical, electrodiagnostic, and sural nerve biopsy data on a group of such patients seen at our institution.
MATERIALS AND METHODS
All patients seen at the University of Michigan Neuromuscular Clinic in the past 5 years who had both a polyneuropathy and an IgA monoclonal gammopathy were identified, and detailed chart reviews were performed. One patient (patient 5) had diabetes mellitus. No patients had systemic cancer, a history of excessive alcohol use, or other disorders (except for diabetes) known to cause neuropathy. All had undergone a comprehensive evaluation to rule out other causes of neuropathy, including physical examination, complete blood count, Westegren sedimentation rate, glucose, glycosylated hemoglobin, glucose tolerance test, electrolytes, BUN, creatinine, liver function tests, thyroid function tests, vitamin BI2 level, VDRL, and chest X-ray. Monoclonal gammopathies were detected by high-resolution agarose gel serum elec- Nerve conduction studies and needle electromyography had been performed on all patients. Motor and antidromic sensory nerve conduction studies were performed using standard techniques of supramaximal percutaneous stimulation and surface electrode recording, maintaining skin temperature 2 32"C, as previously described.' Needle electromyography recordings were performed using standard concentric needle electrodes.
Sural nerve biopsies, received fresh and stretched by adhesion to a piece of cardboard, were divided into three portions. One portion was fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin, Masson trichrome, and Congo red for light microscopy. A second portion was fixed in Karnowski mixture (2.5% glutaraldehyde, 3% formalin) and postfixed in 1% osmium tetroxide; part of this was embedded in Epon for light and electron microscopy, while part was treated with glycerol, 70% and loo%, for teasing. The third portion of the nerve was frozen in liquid nitrogen and treated with fluorescein-conjugated goat antibodies against human IgA, IgG, IgM, C3, C4, and kappa and lambda light chains for evaluation under fluorescent light.
Each teased fiber was graded by a neuropathologist as showing one of five patterns: (1) normal; (2) myelin irregularity (focal myelin thickening at the node of Ranvier or the internode); (3) segmental demyelination-remyelination; (4) axonal degeneration; or (5) axonal regeneration.
The pathologist then generated an overall histological impression of the neuropathy (demyelinating vs. axonal vs. mixed) based on the predominant finding from teased fiber analysis, in conjunction with Epon-embedded light and electron microscopy results.
RESULTS
Of 50 patients seen in our Neuroniuscular Clinic with polyneuropathy and monoclonal or biclonal gammopathy of undetermined significance, 5 (10%) had IgA MGUS. Demographic and immunological features are summarized in Table 1, while clinical features appear in Table 2 . Serum Lower P5/D5
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IgA levels varied from normal (patient 5) to moderately elevated (patient 3), with most patients having mildly elevated serum IgA levels. Urine irnmunoelectrophoresis was normal in 3 of the 5 patients. Serum antibodies to myelin associated glycoprotein (MAG) were absent in patients 1 and 3, and were not assessed in the other patients. 'The polyneuropathy was discovered incidentally in patient 3, who presented for evaluation of back and leg pain, but who was found on examination and electrodiagnostic studies to have a polyneuropathy. Shortly after initial evaluation, he developed painful, distal paresthesias. All other patients presented with complaints of pain, sensory loss, weakness, or a combination of these.
Neurological examination (Table 2 ) revealed weakness which was predominantly distal in 2 patiients, while strength was normal in the others. Sensory loss was present in all. Only patient 1 had total areflexia, though Achilles reflexes were abslent in patients 3 and 4.
Electrodiagnostic data for several representatwe nerves is summarized in Table 3 . Patient 1 was felt to have a primary demyelinating polyneuropathy, and was the only subject whose EMG met formal electrodiagnostic criteria' for chronic inflammatory demyelinating polyneuropathy (CIDP). Patients 2 and 3 had electrodiagnostically mild polyneuropathies, with few to no abnormalities on needle examination. The EMG on patient 4 showed asymmetric denervation, compatible with a mononeuropathy multiplex. A polyradiculoneuropathy was present in patient 5, with prominent paraspinal muscle and distal limb muscle denervation. The findings in patients 1, 2, 3, and 5 were symmetric.
Sural nerve biopsies were performed on patients 2-5. Heterogeneity was clearly present, although most of the biopsies showed a mixed axonal and demyelinating picture. No widening of the myelin lamellae of the type seen in some IgMassociated neuropathies* ',*' was noted. Teased fiber data as well as the overall impression from both light and electron microscopy are provided in Table 4 . While the biopsy of patient 4 did show perivascular mononuclear infiltrates around small epineurial blood vessels, a clear necrotizing vasculitis was not present. Immunofluorescence studies of patients 2, 3, and 4 revealed slight, diffuse Three patients (patients 1, 3 , and 4) were treated. Initial therapy in all consisted of prednisone 60 mg/;ltl, ivhich was gradually tapered. Patient l experienced a mild increase in strength with prednisone, then improved further with monthly intravenous gamma globulin infusions. After 1.5 years, she had only mild ankle dorsiflexor weakness (MRC grade 4+). Patient 3 had pain but no weakness at onset. Treatment resulted in a gradual resolution of the pain over the next 4 months, with an increase in functional capacity. Patient 4, whose main neurological deficit was distal lower extremity weakness, had some increased strength (by one MRC grade) in that muscle group over thc first 2 months of treatment, but then died as a result of his underlying pulmonary disease. Of the untreated patients, patient 2 was lost to follow-up after his diagnostic evaluation, and patient 5 had only sensory symptoms, which were not felt to be sufficiently disabling to warrant the use of prednisone in light of his diabetes.
DISCUSSION
Patients with polyneuropathy and IgM or IgG monoclonal gammopathy are clinically, electrodiagnostically, and histologically heterogenepresumably secondary to more than one mechanism of nerve fiber damage; some have primarily demyelinating neuropathies, while in others the neuropathy shows mainly axonal features. 'I'he best studied are those with IgM monoclonal gammopathy. Among these patients, those with elevated titers of antibodies to myelinassociated glycoprotein (MAG) are felt to form a relatively homogeneous group, presumably secous,Y,lo,l 5 , Ih, I !1--22,2',-29 ondary to a uniform mechanism of nerve damage.
Polyneuropathy occurs less commonly in association with IgA monoclonal gammopathy. Such patients constituted only 10 of 65 patients (15%) with polyneuropathy and MGUS in a recent Mayo Clinic review," and only 5 of 50 cases (10%) seen at our institution with polyneuropathy and monoclonal or biclonal gamrnopathy of undetermined significance. This is roughly comparable with the 12% prevalence of IgA monoclonal gammopathies out of 7004 total patients with MGUS seen over a 27-year period at the Mayo Clinic." Many of the cases of polyneuropathy and IgA MGUS described in the literature have had lambda light chains and osteosclerotic That subgroup is relatively homogeneous, typically resembling CIDP, with motor greater than sensory involvement, elevated cerebrospinal fluid protein levels, and electrodiagnostic studies showing slowed conduction velocities, increased distal latencies, and abnormal temporal dispersion/conduction block.
In contrast, patients with IgA monoclonal gammopathy and peripheral nervous system disease without osteosclerotic myeloma have been varied. Excluding those reported patients who appear to have motor neuron disease, those with malignant plasma cell dyscrasias, and those with osteosclerotic myeloma, there are 6 patients with polyneuropathy in whom the monoclonal gammopathy is of Undetermined significance and who have been well described. Three are single cases,324914 while the other 3 constitute a small series of patients. 23 The clinical characteristics, primary mechanism of nerve damage, and immunological .staining in these 6 patients and our 5 additional patients are summarized in Table 5 .
As can be seen, 3 of the previously described ited to the resolution of paresthesias, and another patient died 2 months into therapy after beginning to show some improved strength. The neuropathy was predominantly demyelinating in one of these patients and predominantly axonal in the other two. This is in agreement with previous reports that patients with either demyelinating or axonal polyneuropathies and IgM or IgG monoclonal gammo athies have responded favorably to Because of the suggestion that imniunornodulatirig therapy may be effective, the nature of the nerve injury should not exclude a trial of such therapy in these patients, at least until more definitive information on treatment is available.
We are unable to clarify the causal relationship, if any, between the monoclonal gammopathy and the polyneuropathy in these atients. This to ic has A causal relationship is considered likely in patients with IgM MGUS and antibodies to MAG, but has not been unequivocally proven. Several factors argue against a direct causal role for the IgA MGUS in our patients: (1) the comparable prevalence of IgA heavy chain in patients with MGUS with and without polyneuropathy ; (2) the presence of a polyradiculoneuropathy in our diabetic patient (patient 5), which was indistinguishable from diabetic polyradiculoneuropathy ; and (3) the lack of selective IgA binding t o specific nerve components. Thus, the MGUS mav be coincidental in our patients, or may simply be an indicator of an underlying autoimmune process. While the apparent response of some of our patients to immunomodulating therapy would support an autoimmune pathogenesis, the process presumably may be directed against a variety of peripheral nerve antigens, given the heterogeneity of clinical, electrodiagnostic, and histological presentations. 
